FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $9,151,934 | -65.8% | 907,930 | -29.6% | 0.13% | -61.4% |
Q3 2022 | $26,744,000 | -8.6% | 1,288,858 | +1.4% | 0.34% | -5.3% |
Q2 2022 | $29,263,000 | -37.0% | 1,270,565 | +0.6% | 0.36% | +5.9% |
Q1 2022 | $46,473,000 | -35.6% | 1,262,866 | +1.6% | 0.34% | -10.3% |
Q4 2021 | $72,209,000 | -0.1% | 1,242,843 | -0.3% | 0.38% | +22.6% |
Q3 2021 | $72,301,000 | -17.2% | 1,246,570 | +21.6% | 0.31% | -9.4% |
Q2 2021 | $87,313,000 | +88.6% | 1,025,519 | +82.6% | 0.34% | +50.7% |
Q1 2021 | $46,304,000 | -5.3% | 561,595 | +4.5% | 0.23% | -18.3% |
Q4 2020 | $48,890,000 | +152.8% | 537,664 | +10.1% | 0.28% | +62.6% |
Q3 2020 | $19,341,000 | +13.2% | 488,399 | -7.4% | 0.17% | -23.7% |
Q2 2020 | $17,085,000 | -58.5% | 527,311 | -71.5% | 0.22% | -42.0% |
Q1 2020 | $41,134,000 | +156.4% | 1,852,018 | +125.9% | 0.39% | +52.6% |
Q4 2019 | $16,044,000 | +22.9% | 819,810 | -2.5% | 0.25% | +9.1% |
Q3 2019 | $13,052,000 | +26.4% | 840,430 | +65.2% | 0.23% | +14.3% |
Q2 2019 | $10,329,000 | – | 508,841 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |